The Mounjaro 5mg SPC: What the Official Prescribing Document Really Tells You

The biggest misreading of the 5mg SPC: that 5mg is a full therapeutic dose for everyone

One of the most common misconceptions people bring to their first consultation is the idea that reaching 5mg means they have arrived at their treatment dose. The SmPC does not frame it that way. The 2.5mg starting dose exists specifically to let the body settle, reducing the likelihood of nausea and other gastrointestinal effects before any meaningful appetite suppression kicks in. The first pen's job is adjustment, not treatment. Moving to 5mg is simply the next step in an escalation schedule that continues through 7.5mg, 10mg, 12.5mg, and up to 15mg, each step taken after at least four weeks at the previous dose.

What the SPC actually says is that 5mg becomes the dose after one month at 2.5mg, and that further increases are considered at four-weekly intervals based on tolerability. The prescriber, not the patient, makes each escalation decision. If you are curious about how the 2.5mg starter dose compares in practical terms, that distinction is worth reading before your first review.

This matters because people sometimes seek out 5mg pens specifically, expecting faster results. The evidence base (including the SURMOUNT-1 trial data cited in NICE's appraisal of tirzepatide) is built around a structured titration, not a fixed dose. Jumping ahead does not replicate those results; it changes the risk profile instead.

What the 5mg SmPC says about who the medicine is licensed for

The SmPC confirms that tirzepatide at any strength, including 5mg, is licensed for adults managing their weight alongside a reduced-calorie diet and increased physical activity. The licensed threshold is a BMI of 30 or above, or a BMI of 27 or above where at least one weight-related condition is present, for example, high blood pressure, type 2 diabetes, dyslipidaemia, or obstructive sleep apnoea.

The SmPC also lists contraindications that every prescriber checks before authorising treatment. These include a personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, and known hypersensitivity to tirzepatide. A history of pancreatitis requires careful prescriber discussion. Pregnancy, breastfeeding, and attempting to conceive are all circumstances in which tirzepatide is not recommended under the SmPC's guidance.

If you want a broader picture of how eligibility works in practice for private treatment, the Mounjaro overview page covers the full clinical picture, including the ethnic-background BMI thresholds recognised in UK guidance.

Side effects mentioned in the 5mg SPC, and how to read them honestly

Spending time with the SmPC's side-effect tables can feel alarming. Lists of adverse reactions are comprehensive by design, the SPC must capture everything reported across clinical trials, including rare events. The most frequently reported effects at 5mg, as reflected in the SmPC and consistent with NHS guidance, are gastrointestinal: nausea, vomiting, diarrhoea, constipation, and indigestion tend to peak shortly after starting or after a dose increase, then ease for most people over days to a couple of weeks.

The SmPC also flags acute pancreatitis as a known but infrequent risk. Anyone experiencing severe, persistent abdominal pain that radiates to the back (with or without vomiting) should stop treatment and seek urgent medical attention. That is the SmPC's instruction, and it is echoed in MHRA safety communications.

Injection-site reactions, fatigue, headache, and dizziness appear in the SmPC's frequency tables as common. Less common effects include heart rate increase and hypersensitivity reactions. The full list is in your Patient Information Leaflet, which is the patient-facing companion to the SmPC and uses plainer language. A prescriber can walk you through what is relevant to your own health history, it is a question our prescribers hear most weeks.

Storage, handling, and what the SPC says about the 5mg KwikPen format

The Mounjaro 5mg KwikPen delivers four once-weekly doses from a single pen. The SmPC specifies refrigerated storage between 2°C and 8°C. A room-temperature window is permitted, but the SmPC's exact duration for that window should always be taken from your Patient Information Leaflet or confirmed with your pharmacist, no secondary summary should be your reference point for storage timing, because getting it wrong affects the medicine's efficacy.

The pen should not be frozen, and it should be kept away from direct light and heat. The SmPC states that the pen should be inspected before each use: the solution should be clear to slightly opalescent and colourless to slightly yellow; do not use it if particles are visible or if it has been frozen.

For practical questions about the 5mg KwikPen itself (including the injection process) the Patient Information Leaflet inside your box is the authoritative guide. The SmPC provides the prescriber-level detail; the PIL translates that into step-by-step instructions for the person using it. If you are considering whether 5mg is the right next step after your starter month, the 5mg dose guide gives more context on how that clinical conversation typically goes. For a sense of what private treatment costs across the titration schedule, the Mounjaro price page sets out the landscape honestly.

If you would like a prescriber to review your suitability for Mounjaro, including where 5mg fits in your treatment journey, speak to our prescribers through a free consultation, reviewed the same day, with no obligation.